ROTASIIL

ROTASIIL (BRV-PV) is a live attenuated, oral, pentavalent rotavirus vaccine developed by the Serum Institute of India. It is composed of five human-bovine reassortant rotavirus strains representing the G1, G2, G3, G4, and G9 serotypes. The vaccine is indicated for the prevention of rotavirus gastroenteritis in infants, typically administered in a three-dose schedule at 6, 10, and 14 weeks of age. A distinguishing feature of ROTASIIL is its thermostability, which allows it to remain stable at temperatures up to 25°C, reducing the reliance on a continuous cold chain for storage and distribution. It received WHO prequalification in 2018 and is used globally, particularly in low- and middle-income countries.

Brand names

ROTASIIL

Other names

Live Attenuated Pentavalent Human X Bovine Reassortant Rotavirus VaccineBovine-Human Reassortant Pentavalent Rotavirus VaccinePentavalent Rotavirus Vaccine